GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Cash Flow from Investing

US Stem Cell (US Stem Cell) Cash Flow from Investing : $0.00 Mil (TTM As of Dec. 2022)


View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2022, US Stem Cell spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, US Stem Cell gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2022.


US Stem Cell Cash Flow from Investing Historical Data

The historical data trend for US Stem Cell's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Cash Flow from Investing Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.17 - - -

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

US Stem Cell Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

US Stem Cell's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

US Stem Cell's Cash Flow from Investing for the quarter that ended in Dec. 2022 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


US Stem Cell  (OTCPK:USRM) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

US Stem Cell's purchase of property, plant, equipment for the three months ended in Dec. 2022 was $0.00 Mil. It means US Stem Cell spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

US Stem Cell's sale of property, plant, equipment for the three months ended in Dec. 2022 was $0.00 Mil. It means US Stem Cell gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

US Stem Cell's purchase of business for the three months ended in Dec. 2022 was $0.00 Mil. It means US Stem Cell spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

US Stem Cell's sale of business for the three months ended in Dec. 2022 was $0.00 Mil. It means US Stem Cell gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

US Stem Cell's purchase of investment for the three months ended in Dec. 2022 was $0.00 Mil. It means US Stem Cell spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

US Stem Cell's sale of investment for the three months ended in Dec. 2022 was $0.00 Mil. It means US Stem Cell gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

US Stem Cell's net Intangibles purchase and sale for the three months ended in Dec. 2022 was $0.00 Mil. It means US Stem Cell paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

US Stem Cell's cash from discontinued investing activities for the three months ended in Dec. 2022 was 0.00 Mil. It means US Stem Cell paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

US Stem Cell's cash from other investing activities for the three months ended in Dec. 2022 was $0.00 Mil. It means US Stem Cell paid $0.00 Mil for other investing activities.


US Stem Cell Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


US Stem Cell (US Stem Cell) Business Description

Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
Murphy William P Jr director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson director 14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman director 5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart director 19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson director 1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella officer: Chief Science Officer 1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee director 54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth director 1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich officer: Vice President,Sales&Marketing 482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson director 11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt director, 10 percent owner, officer: Executive Chairman & CTO 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott officer: VP of Public Relations 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325

US Stem Cell (US Stem Cell) Headlines